Cyclerion Therapeutics (CYCN) Return on Capital Employed (2019 - 2025)
Cyclerion Therapeutics (CYCN) recorded quarterly Return on Capital Employed of 40.3% in Q3 2025, up 5.47% quarter-over-quarter from 42.63% in Q2 2025, and up 2717.0% on a YoY basis from 1.43% in Q3 2024.
Cyclerion Therapeutics (CYCN) Return on Capital Employed (2019 - 2025) Analysis & Trends
Cyclerion Therapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 40.3% for Q3 2025.
- In Q3 2025, Return on Capital Employed rose 2717.0% year-over-year to 40.3%; the TTM figure through Sep 2025 stood at 40.3% (up 2717.0% YoY), while the FY2024 annual figure was 33.75%, up 6119.0% from the prior year.
- Return on Capital Employed was 40.3% for Q3 2025 at Cyclerion Therapeutics, up from 42.63% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 40.11% in Q1 2025 to a low of 354.88% in Q1 2023.
- Historically, Return on Capital Employed has averaged 128.29% across 5 years, with a median of 105.23% in 2021.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 22876 bps in 2023, then jumped 25154 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 105.23% in 2021, then plunged by 141 bps to 253.89% in 2022, then jumped by 58 bps to 106.08% in 2023, then surged by 60 bps to 42.62% in 2024, then grew by 5 bps to 40.3% in 2025.
- The last three Return on Capital Employed figures came in at 40.3% (Q3 2025), 42.63% (Q2 2025), and 40.11% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Cyclerion Therapeutics | 11.50 Mn | 8.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -40.30% |
| Jun 30, 2025 | -42.63% |
| Mar 31, 2025 | -40.11% |
| Dec 31, 2024 | -42.62% |
| Sep 30, 2024 | -67.47% |
| Jun 30, 2024 | -114.62% |
| Mar 31, 2024 | -103.34% |
| Dec 31, 2023 | -106.08% |
| Sep 30, 2023 | -151.34% |
| Jun 30, 2023 | -242.10% |
| Mar 31, 2023 | -354.88% |
| Dec 31, 2022 | -253.89% |
| Sep 30, 2022 | -209.56% |
| Jun 30, 2022 | -167.78% |
| Mar 31, 2022 | -126.12% |
| Dec 31, 2021 | -105.23% |
| Sep 30, 2021 | -99.50% |
| Jun 30, 2021 | -91.25% |
| Mar 31, 2021 | -78.63% |
| Dec 31, 2020 | -76.35% |